NL-OMON25587尚未招募不适用
A randomised trial of dose escalation in definitive chemoradiotherapy for patients with oesophageal cancer.
dept of Radiotherapy, AMC, AmsterdamArhems Radiotherapeutisch Institute, Arnhemdept of oncology, Erasmusmc, Rotterdam0 个研究点目标入组 260 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. T1-4, N0-3,M0 medically or technically inoperable esophageal or junction tumors;
- •2. Histology proven;
排除标准
- •1. Esophageal fistula;
- •2. Both pathological nodes at supraclavicular and truncus coeliacus level;
研究者
相似试验
已完成
3 期
A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer *ART DECO*esophagus cancerOesophageal cancer10017990NL-OMON41614Academisch Medisch Centrum260
进行中（未招募）
1 期
An investigation to investigate whether a single dose of XEN-D0501 is tolerable by type 2 diabetic patients prior to multiple dose trials (to investigate if the compound can effectively regulate diabetes)Type 2 diabetesEUCTR2016-003843-12-DKPILA PHARMA26
进行中（未招募）
不适用
Randomized continuation, dose escalation trial of Sorafenib in pts with advanced HCC with radiological progression on prior sorafenib treatment (Phase II study) - ONC-2006-004MedDRA version: 9.1Level: LLTClassification code 10019695Term: Hepatic neoplasmHepatocellular carcinomaEUCTR2007-000758-30-ITISTITUTO CLINICO HUMANITAS
已完成
不适用
A randomised controlled dose intensification clinical trial of chemotherapy with or without recombinant human granulocyte colony stimulating factor (G-CSF) in small cell lung cancer (SCLC)ung cancerSmall cell lung cancer (SCLC)CancerISRCTN15921116Medical Research Council (MRC) (UK)400
进行中（未招募）
不适用
A Dose-Escalation, Randomized Phase I/II trial of Zalutumumab - a Human Monoclonal Anti-EGF receptor Antibody - With or Without Irinotecan chemotherapy in Cetuximab refractory Colorectal Cancer patients Who Have Failed Standard Chemotherapy and Progressed During or Within 6 months of Stopping Cetuximab-Based Therapy. - Zalutumumab with or without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal CancerEUCTR2007-005690-59-BEGenmab A/S97